Antinociception by spinal and systemic oxycodone: Why does the route make a difference? In vitro and in vivo studies in rats

Anesthesiology

Volumn 105, Issue 4, 2006, Pages 801-812

  Lemberg, Kim K ^a,b   Kontinen, Vesa K ^c   Siiskonen, Antti O ^b   Viljakka, Kaarin M ^c   Yli Kauhaluoma, Jari T ^b   Korpi, Esa R ^a   Kalso, Eija A ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NORBINALTORPHIMINE; NOROXYCODONE; OXYCODONE; OXYMORPHONE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; AUTORADIOGRAPHY; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; EXPERIMENTAL TEST; HOT PLATE TEST; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; SEDATION; SPINAL CORD; TAIL FLICK TEST;

ALGORITHMS; ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; AUTORADIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; MALE; MORPHINANS; MORPHINE; MOTOR ACTIVITY; OXYCODONE; OXYMORPHONE; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 33749175958     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/00000542-200610000-00027     Document Type: Article

References (47)

1. Poyhia R, Seppala T, Olkkola KT, Kalso E: The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33:617-21
2. Osborne R, Joel S, Trew D, Slevin M: Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47:12-9
3. Poyhia R, Seppala T: Liposolubility and protein binding of oxycodone in vitro. Pharmacol Toxicol 1994; 74:23-7
4. Chen Y, Mestek A, Liu J, Hurley JA, Yu L: Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 1993; 44:8-12
5. Chen Y, Mestek A, Liu J, Yu L: Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J 1993; 295:625-8
6. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG: The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci U S A 1992; 89:12048-52
7. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, Bell GI: Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A 1993; 90:6736-40
8. Evans CJ, Keith DE, Jr., Morrison H, Magendzo K, Edwards RH: Cloning of a delta opioid receptor by functional expression. Science 1992; 258:1952-5
9. Henderson G, McKnight AT: The orphan opioid receptor and its endogenous ligand-nociceptin/orphanin FQ. Trends Pharmacol Sci 1997; 18:293-300
10. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B: Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377:532-5
11. Monory K, Greiner E, Sartania N, Sallai L, Pouille Y, Schmidhammer H, Hanoune J, Borsodi A: Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 1999; 64:2011-20
12. Chen ZR, Irvine RJ, Somogyi AA, Bochner F: Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48:2165-71
13. Beardsley PM, Aceto MD, Cook CD, Bowman ER, Newman JL, Harris LS: Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. Exp Clin Psychopharmacol 2004; 12:163-72
14. Poyhia R, Olkkola KT, Seppala T, Kalso E: The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 1991; 32:516-8
15. Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T: Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991; 35:642-6
16. Backlund M, Lindgren L, Kajimoto Y, Rosenberg PH: Comparison of epidural morphine and oxycodone for pain after abdominal surgery. J Clin Anesth 1997; 9:30-5
17. Yanagidate F, Dohi S: Epidural oxycodone or morphine following gynaecological surgery. Br J Anaesth 2004; 93:362-7
18. Plummer JL, Cmielewski PL, Reynolds GD, Gourlay GK, Cherry DA: Influence of polarity on dose-response relationships of intrathecal opioids in rats. Pain 1990; 40:339-47
19. Poyhia R, Kalso EA: Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. Pharmacol Toxicol 1992; 70:125-30
20. Leow KP, Smith MT: The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 1994; 54:1229-36
21. Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW: Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 1983; 11:446-50
22. Ishida T, Oguri K, Yoshimura H: Determination of oxycodone metabolites in urines and feces of several mammalian species. J Pharm Dyn 1982; 5:521-5
23. Ishida T, Oguri K, Yoshimura H: Isolation and identification of urinary metabolites of oxycodone in rabbits. Drug Metab Dispos 1979; 7:162-5
24. Ishida T, Oguri K, Yoshimura H: A novel metabolite of oxycodone in the urine of rabbits. J Pharm Dyn 1982; 5:134-6
25. Weinstein SH, Gaylord JC: Determination of oxycodone in plasma and identification of a major metabolite. J Pharm Sci 1979; 68:527-8
26. Briggs SL, Sawyer DC, Rech RH, Galligan JJ: Oxymorphone-induced analgesia and colonic motility measured in colorectal distension. Pharmacol Biochem Behav 1995; 52:561-3
27. Bolan EA, Tallarida RJ, Pasternak GW: Synergy between mu opioid ligands: Evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 2002; 303:557-62
28. Beaver WT, Feise GA: A comparison of the analgesic effect of oxymorphone by rectal suppository and intramuscular injection in patients with postoperative pain. J Clin Pharmacol 1977; 17:276-91
29. Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T: Morphine and oxycodone in the management of cancer pain: Plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990; 67:322-8
30. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16:109-10
31. Cheng CY, Hsin LW, Lin YP, Tao PL, Jong TT: N-cubylmethyl substituted morphinoids as novel narcotic antagonists. Bioorg Med Chem 1996; 4:73-80
32. Iijima I, Minamikawa J, Jacobson AE, Brossi A, Rice KC: Studies in the (+)-morphinan series: 5. Synthesis and biological properties of (+)-naloxone. J Med Chem 1978; 21:398-400
33. Coop A, Janetka JW, Lewis JW, Rice KC: L-Selectride as a general reagent for the O-demethylation and N-decarbomethoxylation of opium alkaloids and derivates. J Org Chem 1998; 63:4392-6
34. Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17:1031-6
35. Laitinen JT: Selective detection of adenosine A1 receptor-dependent G-protein activity in basal and stimulated conditions of rat brain [35S]guanosine 5′-(gamma-thio)triphosphate autoradiography. Neuroscience 1999; 90:1265-79
36. Laitinen JT, Jokinen M: Guanosine 5′-(gamma-[35S]thio)triphosphate autoradiography allows selective detection of histamine H3 receptor-dependent G protein activation in rat brain tissue sections. J Neurochem 1998; 71:808-16
37. Sim LJ, Selley DE, Childers SR: In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[gamma-[35S]thio]-triphosphate binding. Proc Natl Acad Sci U S A 1995; 92:7242-6
38. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther 2004; 308:547-54
39. Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR: Mu-opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: Signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 1997; 51:87-96
40. Traynor JR, Nahorski SR: Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1995; 47:848-54
41. Maher CE, Selley DE, Childers SR: Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions. Biochem Pharmacol 2000; 59:1395-401
42. Sim LJ, Selley DE, Dworkin SI, Childers SR: Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPγS autoradiography in rat brain. J Neurosci 1996; 16:2684-92
43. Ross FB, Smith MT: The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997; 73:151-7
44. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD: Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59:52-61
45. Heiskanen T, Olkkola KT, Kalso E: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64:603-11
46. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32:447-54
47. Xu M, Wei H, Kontinen VK, Kalso E, Pertovaara A: The dissociation of sedative from spinal antinociceptive effects following administration of a novel alpha-2-adrenoceptor agonist, MPV-2426, in the locus coeruleus in the rat. Acta Anaesth Scand 2000; 44:648-55